Abbott Initiates LIFE-BTK Trial to Evaluate the Esprit BTK Drug-Eluting Resorbable Scaffold

 Abbott Initiates LIFE-BTK Trial to Evaluate the Esprit BTK Drug-Eluting Resorbable Scaffold

Abbott Initiates LIFE-BTK Trial to Evaluate the Esprit BTK Drug-Eluting Resorbable Scaffold

Shots:

  • The LIFE-BTK study is the first IDE trial in the US to evaluate a fully resorbable device for treating blocked arteries below the knees, or CLI, in people with advanced stages of PAD. The study will assess Esprit BTK resorbable scaffold in 225 patients across the globe
  • The focus of the study is to evaluate the safety & efficacy of the device in CLI patients with up to two lesions in separate infrapopliteal vessels. Currently, there are no stents or drug-coated balloons approved for use below the knee in the US
  • The Esprit BTK System consists of a thin strutted scaffold which measures 99 microns made from PLLA, a semi-crystalline bioresorbable polymer engineered to resist vessel recoil, providing a platform for drug delivery and has received the US FDA’s BDD, which streamlines the review and pre-market approval timelines

Click here ­to­ read full press release/ article | Ref: Abbott | Image: Flipboard

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post